Clinical trial
A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK111 in Healthy Subjects
NCT03622021 is registered in ClinicalTrials.gov with Akesobio Australia Pty Ltd as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Phase 1, Randomized, Double-Blind, Placebo-Controlled, Single Dose-Escalation First-In-Human Study Evaluating the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of AK111 in Healthy Subjects
- Lead sponsor
- Akesobio Australia Pty Ltd
- Phase
- Phase 1
- Overall status
- Completed
- Start date
- August 14, 2018
- Completion date
- September 9, 2019
- Enrollment
- 68 (actual)
- Sites
- 1
Conditions
As the registry lists them; a condition with its own page is linked.